'Full treatment effect' presentation slideshows

Surrogate Endpoints in Infectious Diseases Trials: FDA Perspective

Surrogate Endpoints in Infectious Diseases Trials: FDA Perspective. John H. Powers, MD Lead Medical Officer Antimicrobial Drug Development and Resistance Initiatives Office of Drug Evaluation IV Center for Drug Evaluation and Research U.S. Food and Drug Administration. Introduction.

642 views • 30 slides